OK Biotech Co., Ltd. (4155.TW)
TWD 20.9
(-0.71%)
TWD 20.9
(-0.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 87.24 Million TWD | -64.19% |
| 2022 | 247.47 Million TWD | 165.71% |
| 2021 | 85.45 Million TWD | -52.22% |
| 2020 | 171.23 Million TWD | 16.48% |
| 2019 | 164.34 Million TWD | -21.82% |
| 2018 | 201.69 Million TWD | 26.84% |
| 2017 | 145.72 Million TWD | 17.9% |
| 2016 | 133.88 Million TWD | -10.03% |
| 2015 | 153.9 Million TWD | 53.35% |
| 2014 | 86.63 Million TWD | -36.14% |
| 2013 | 176.43 Million TWD | 53.91% |
| 2012 | 118.85 Million TWD | 31.65% |
| 2011 | 88.79 Million TWD | 88.03% |
| 2010 | 48.26 Million TWD | -25.71% |
| 2009 | 64.85 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 39.84 Million TWD | 502.74% |
| 2024 Q2 | 48.09 Million TWD | 1.22% |
| 2023 Q4 | -29.56 Million TWD | -177.0% |
| 2023 FY | - TWD | -64.19% |
| 2023 Q1 | 34.01 Million TWD | 93.92% |
| 2023 Q3 | 38.4 Million TWD | -32.94% |
| 2023 Q2 | 57.26 Million TWD | 68.36% |
| 2022 Q3 | 89.11 Million TWD | -7.94% |
| 2022 Q1 | 76.04 Million TWD | 235.97% |
| 2022 FY | - TWD | 165.71% |
| 2022 Q4 | 17.53 Million TWD | -80.32% |
| 2022 Q2 | 96.8 Million TWD | 27.3% |
| 2021 Q1 | 39.78 Million TWD | -33.98% |
| 2021 FY | - TWD | -52.22% |
| 2021 Q4 | 22.63 Million TWD | -6.76% |
| 2021 Q3 | 24.27 Million TWD | 251.06% |
| 2021 Q2 | 6.91 Million TWD | -82.62% |
| 2020 Q4 | 60.25 Million TWD | 37.27% |
| 2020 Q2 | 38.96 Million TWD | -49.43% |
| 2020 FY | - TWD | 16.48% |
| 2020 Q1 | 77.05 Million TWD | 86.5% |
| 2020 Q3 | 43.89 Million TWD | 12.64% |
| 2019 Q1 | 40.61 Million TWD | -34.12% |
| 2019 Q3 | 63.11 Million TWD | 43.48% |
| 2019 Q2 | 43.98 Million TWD | 8.32% |
| 2019 Q4 | 41.31 Million TWD | -34.53% |
| 2019 FY | - TWD | -21.82% |
| 2018 Q2 | 56.98 Million TWD | -10.97% |
| 2018 Q3 | 59.15 Million TWD | 3.8% |
| 2018 Q4 | 61.64 Million TWD | 4.21% |
| 2018 FY | - TWD | 26.84% |
| 2018 Q1 | 64.01 Million TWD | 64.72% |
| 2017 Q3 | 59.18 Million TWD | 6.68% |
| 2017 Q4 | 38.86 Million TWD | -34.34% |
| 2017 FY | - TWD | 17.9% |
| 2017 Q1 | 37.12 Million TWD | 23.36% |
| 2017 Q2 | 55.47 Million TWD | 49.41% |
| 2016 FY | - TWD | -10.03% |
| 2016 Q3 | 22.52 Million TWD | -58.41% |
| 2016 Q4 | 30.09 Million TWD | 33.6% |
| 2016 Q2 | 54.16 Million TWD | -1.34% |
| 2016 Q1 | 54.9 Million TWD | 59.31% |
| 2015 FY | - TWD | 53.35% |
| 2015 Q4 | 34.46 Million TWD | 0.0% |
| 2015 Q3 | 34.46 Million TWD | -6.48% |
| 2015 Q2 | 36.85 Million TWD | 0.0% |
| 2015 Q1 | 36.85 Million TWD | 225.68% |
| 2014 Q1 | 22.45 Million TWD | -39.37% |
| 2014 Q2 | 22.45 Million TWD | 0.0% |
| 2014 Q4 | 11.31 Million TWD | 0.0% |
| 2014 Q3 | 11.31 Million TWD | -49.61% |
| 2014 FY | - TWD | -36.14% |
| 2013 Q2 | 44.38 Million TWD | 0.0% |
| 2013 Q1 | 44.38 Million TWD | 39.23% |
| 2013 Q3 | 37.03 Million TWD | -16.56% |
| 2013 Q4 | 37.03 Million TWD | 0.0% |
| 2013 FY | - TWD | 53.91% |
| 2012 FY | - TWD | 31.65% |
| 2012 Q3 | 31.88 Million TWD | 0.0% |
| 2012 Q4 | 31.88 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 FY | - TWD | 88.03% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2010 FY | - TWD | -25.71% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 968.55 Million TWD | 90.992% |
| Apex Medical Corp. | 318.12 Million TWD | 72.575% |
| Applied BioCode Corporation | -98.59 Million TWD | 188.491% |